Ginkgo Bioworks Holdings (DNA) Operating Leases (2022 - 2026)

Ginkgo Bioworks Holdings has reported Operating Leases for 5 years, with the latest figure at $410.7 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 5.49% year-over-year to $410.7 million; the trailing twelve-month figure through Mar 2026 stood at $410.7 million (down 5.49% YoY), and the FY2025 full-year result was $417.1 million, down 4.94% from the prior year.
• Operating Leases for Q1 2026 stood at $410.7 million, down from $417.1 million in the prior quarter.
• The five-year high for Operating Leases was $452.3 million in Q2 2024, with the low at $221.8 million in Q4 2023.
• Historically, Operating Leases has averaged $395.6 million across 5 years, with a median of $415.2 million in 2022.
• Annual changes were most pronounced in 2023 — Operating Leases tumbled 46.32% — and 2024, when it jumped 97.79%.
• Ginkgo Bioworks Holdings' Operating Leases stood at $413.3 million in 2022, then tumbled by 46.32% to $221.8 million in 2023, then soared by 97.79% to $438.8 million in 2024, then declined by 4.94% to $417.1 million in 2025, then declined by 1.53% to $410.7 million in 2026.
• The last three Operating Leases figures came in at $410.7 million (Q1 2026), $417.1 million (Q4 2025), and $422.9 million (Q3 2025), per Business Quant data.